Next |
home / stock / nvcr / nvcr message board
Subject | By | Source | When |
---|---|---|---|
You go to $NWBO MB and thumsy up | KIPK | investorshub | 04/28/2023 3:58:51 PM |
LOL - THI HAT HAS NO CHNCE. THE | KIPK | investorshub | 04/28/2023 1:02:50 PM |
$NVCR has a great chance of retaking the | whosleftholdindabag | investorshub | 04/27/2023 9:21:22 PM |
Won't make a diff. SP will continue to | KIPK | investorshub | 04/27/2023 12:44:45 PM |
Results of LUNAR at ASCO. Also, nine other | jondoeuk | investorshub | 04/26/2023 6:00:33 PM |
LOL - Sounds like Jonk to me | KIPK | investorshub | 04/21/2023 12:16:28 PM |
LOL - NoCure has no future - Just | KIPK | investorshub | 04/21/2023 12:15:07 PM |
Crash, $NVCR has a MUCH brighter future than | whosleftholdindabag | investorshub | 04/20/2023 10:42:10 PM |
The PR https://www.businesswire.com/news/home/20230413005882/en/Novocure-Announc | jondoeuk | investorshub | 04/14/2023 8:26:19 PM |
As someone once said, ''Never argue with an | jondoeuk | investorshub | 04/13/2023 10:07:17 PM |
Novocure has no product that works. | CrashOverride | investorshub | 04/13/2023 3:52:21 PM |
Rarely do I capitalize on buying at the | whosleftholdindabag | investorshub | 04/13/2023 12:15:18 PM |
Opinion (bad one) And for someone who is always | Legend431 | investorshub | 03/28/2023 1:57:48 PM |
Optune, junk science! | CrashOverride | investorshub | 03/28/2023 3:53:06 AM |
Can you believe this 18 months ago was | Zadie420 | investorshub | 03/19/2023 4:32:01 PM |
You missing the fact that the tinfoil is | KIPK | investorshub | 03/19/2023 1:52:28 PM |
Quoting AACR the only one to publish Adam | The Danish Dude | investorshub | 03/19/2023 10:54:08 AM |
Also, | jondoeuk | investorshub | 03/18/2023 3:49:51 AM |
AACR abstracts (the event is next month). | jondoeuk | investorshub | 03/18/2023 3:19:48 AM |
Simply put, no. | jondoeuk | investorshub | 03/17/2023 11:46:11 PM |
News, Short Squeeze, Breakout and More Instantly...
NovoCure Limited Company Name:
NVCR Stock Symbol:
NASDAQ Market:
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was...
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, i...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three mo...